Savara (NASDAQ:SVRA) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright initiated coverage on shares of Savara (NASDAQ:SVRA) in a report published on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 price objective on the stock.

A number of other analysts also recently commented on the company. Royal Bank Of Canada set a $10.00 price target on Savara in a research report on Wednesday, October 7th. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Citigroup restated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.29.

Savara Trading Down 1.7%

Shares of SVRA stock opened at $4.64 on Thursday. Savara has a 52-week low of $4.13 and a 52-week high of $7.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 10.13 and a current ratio of 8.55. The company has a 50-day simple moving average of $4.93 and a two-hundred day simple moving average of $5.34. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.61 and a beta of 0.32.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. Research analysts anticipate that Savara will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP lifted its position in shares of Savara by 2.1% during the 3rd quarter. Marshall Wace LLP now owns 6,386,775 shares of the company’s stock valued at $32,956,000 after buying an additional 129,786 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Savara by 2.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company’s stock worth $36,828,000 after acquiring an additional 160,349 shares during the period. Nan Fung Trinity HK Ltd. grew its stake in shares of Savara by 1,088.3% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after acquiring an additional 1,687,310 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Savara during the 3rd quarter worth $54,000. Finally, Profund Advisors LLC increased its holdings in Savara by 7.3% in the 3rd quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock worth $257,000 after acquiring an additional 3,370 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.